Clinton Yam, MD, reflects on the guidance that he received from an important mentor he had during his fellowship, Dr Stacy Moulder. Dr Yam recalls his mentor's strong advocacy and personalized response-adapted approach for patients with treatment-resistant triple-negative breast cancer (TNBC).
Dr Moulder's approach to treating early TNBC involves starting all patients on standard therapy and then conducting an early on-treatment response to better personalize disease management. This approach developed into the ARTEMIS clinical trial, among others, and is what Dr Yam considers to be the "way of the future" in the management of patients with early TNBC.
Medscape © 2022 WebMD, LLC
Any views expressed above are the author's own and do not necessarily reflect the views of WebMD or Medscape.
Cite this: A Mentor Who Helped Show the 'Way of the Future' in the Treatment of Early TNBC - Medscape - Jul 29, 2022.